Hagerty; David

Patent Applications and Registrations

Patent applications and USPTO patent grants for Hagerty; David.The latest application filed is for "methods for treating scleroderma by administering a soluble ctla4 molecule".

Company Profile

0.10.11

Hagerty; David - Cardiff by the Sea CA
Hagerty; David - Pennington NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule Grant 10,052,360 - Cohen , et al. August 21, 2	2018-08-21
Methods For Treating Scleroderma By Administering A Soluble Ctla4 Molecule App 20160158318 - COHEN; Robert ; et al.	2016-06-09
Methods for treating scleroderma by administering a soluble CTLA4 molecule Grant 9,296,808 - Cohen , et al. March 29, 2	2016-03-29
Methods For Treating Scleroderma By Administering A Soluble Ctla4 Molecule App 20140286948 - COHEN; Robert ; et al.	2014-09-25
Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule Grant 8,722,632 - Cohen , et al. May 13, 2	2014-05-13
Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule Grant 8,703,718 - Cohen , et al. April 22, 2	2014-04-22
Methods For Treating Juvenile Rhumatoid Arthritis By Administering A Soluble Ctla4 Molecule App 20130251713 - COHEN; ROBERT ; et al.	2013-09-26
Methods For Treating Sjogrens Syndrome By Administering A Soluble Ctla4 Molecule App 20130230518 - COHEN; ROBERT ; et al.	2013-09-05
Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule Grant 8,497,247 - Cohen , et al. July 30, 2	2013-07-30
Method For Treating A Rheumatic Disease Using A Soluble Ctla4 Molecule App 20120258094 - Cohen; Robert ; et al.	2012-10-11
Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID Grant 8,227,420 - Cohen , et al. July 24, 2	2012-07-24
Method for treating a rheumatic disease using a soluble TLA4 molecule Grant 8,148,332 - Cohen , et al. April 3, 2	2012-04-03
Method For Treating A Rheumatic Disease Using A Soluble Tla4 Molecule App 20110311529 - Cohen; Robert ; et al.	2011-12-22
Method For Treating An Autoimmune Disease Using A Soluble Ctla4 Molecule And A Dmard Or Nsaid App 20100166756 - COHEN; ROBERT ; et al.	2010-07-01
Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules App 20100041602 - Hagerty; David ; et al.	2010-02-18
Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules Grant 7,482,327 - Hagerty , et al. January 27, 2	2009-01-27
Methods for treating immune system diseases using a soluble CTLA4 molecule Grant 7,455,835 - Cohen , et al. November 25, 2	2008-11-25
Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules App 20070009511 - Hagerty; David ; et al.	2007-01-11
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID App 20040022787 - Cohen, Robert ; et al.	2004-02-05
Methods for treating rheumatic diseases using a soluble CTLA4 molecule App 20030083246 - Cohen, Robert ; et al.	2003-05-01

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.